NEW YORK (GenomeWeb News) – Affymetrix today said that that it has penned a five-year gene-expression collaboration with the Peter MacCallum Cancer Centre in Australia.
 
Terms of the agreement call for Peter Mac researchers to use Affymetrix GeneChip technology for translational research projects. The first studies will cover ovarian cancer and carcinoma of unknown primaries.
 
Millennium Science will supply Peter Mac with Affy’s technology and provide technical support.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times reports that as China invests in science, it also is dealing with research fraud.

In PLOS this week: transcriptome study of a cold-tolerant plant, deep sequencing of clinical influenza A samples, and more.

The Atlantic writes that retrotransposons like BovB have proliferated in a number of genomes.

Researchers have sequenced the genome of a man who lived in China some 40,000 years ago, according to UPI.